
EvolutionaryScale is a life sciences company focused on developing frontier AI for protein modeling. Their flagship product, ESM3, is a generative language model that reasons over protein sequence, structure, and function, enabling scientists to understand, imagine, and create proteins. ESM3 has demonstrated capabilities in designing novel proteins, such as esmGFP, which simulates over 500 million years of natural protein evolution. The company also offers ESM Cambrian, a parallel model family focused on protein representation learning. EvolutionaryScale emphasizes responsible AI development and offers its models through an API and on platforms like AWS SageMaker and NVIDIA BioNemo, with open-source options available for research. Their business model appears to revolve around API access, partnerships, and potentially licensing of their advanced models for commercial applications in drug discovery and other areas.

EvolutionaryScale is a life sciences company focused on developing frontier AI for protein modeling. Their flagship product, ESM3, is a generative language model that reasons over protein sequence, structure, and function, enabling scientists to understand, imagine, and create proteins. ESM3 has demonstrated capabilities in designing novel proteins, such as esmGFP, which simulates over 500 million years of natural protein evolution. The company also offers ESM Cambrian, a parallel model family focused on protein representation learning. EvolutionaryScale emphasizes responsible AI development and offers its models through an API and on platforms like AWS SageMaker and NVIDIA BioNemo, with open-source options available for research. Their business model appears to revolve around API access, partnerships, and potentially licensing of their advanced models for commercial applications in drug discovery and other areas.
What they do: Develop frontier generative AI models for protein sequence, structure, and function (ESM3 family)
Founded: 2023
HQ: New York, NY
Recent funding: $142M seed (June 25, 2024)
Notable partners/investors: Amazon Web Services, NVentures (NVIDIA), Nat Friedman, Daniel Gross, Lux Capital
Protein modeling and design for life-sciences applications (drug discovery, enzymes, materials science).
2023
Biotechnology
142000000
Participation from Amazon Web Services and NVentures (NVIDIA)
“Strategic participation from AWS and NVentures (NVIDIA) indicates partnerships with major cloud and GPU platform providers.”